( PRINCETON N.J.--(BUSINESS WIRE)--Jun 2...)Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop,Health

PRINCETON, N.J.--(BUSINESS WIRE)--Jun 28, 2007 - Cytogen Corporation (NASDAQ: CYTO) reported updated data from a Phase 1 dose escalation study evaluating QUADRAMET(R) (samarium Sm-153 lexidronam injection) in combination with bortezomib (Velcade(R), Millennium Pharmaceuticals, Inc.) in patients with relapsed multiple myeloma. Data from 33 patients were presented today in a poster titled, "Phase 1 Trial of Bortezomib (Vel) and Samarium (Sam) in Multiple Myeloma," by James Berenson, M.D., Medical & Scientific Director of the Institute for Myeloma & Bone Cancer Research in West Hollywood, California, at the XIth International Myeloma Workshop taking place in Greece.

Results from this study demonstrated that the combination was tolerable and of 32 evaluable patients, 15 participants, or more than 46% achieved a response or stabilization of their disease. Of these, six patients responded to the combination regimen, with three achieving a complete response (CR) and three achieving a minor response (MR). Of the 15 patients who achieved either a response to treatment or stabilization of their disease, nine had previously failed treatment with bortezomib.

"For years we have known that radiopharmaceuticals, such as QUADRAMET, are an effective palliative treatment for patients with metastatic bone disease," said Michael D. Becker, president and chief executive officer of Cytogen. "The data from this Phase 1 study suggest that administration of QUADRAMET is safe and may also have anticancer activity when used in combination with bortezomib and should be studied further in this setting. Cytogen is committed to developing and commercializing innovative products, like QUADRAMET, for cancer patients, and these results support our ongoing development plan investigating additional synergistic combinations and patient populations that may benefit from this important therapy."

Previously published preclinical
'"/>

Page: 1 2 3 4 5 6 7 8
Related medicine technology :

1. Vion Pharmaceuticals Presents Clinical Data from a Phase II Trial of Cloretazine (VNP40101M) in Elderly AML Patients with Unfavorable Cytogenetics at EHA Meeting
2. New Data for Cytogens QUADRAMET Reported at Annual ASCO Meeting
3. Cytogen Reports Publication Validating the Utility of its Proprietary ProChart Database
4. Preclinical Data on Cytogens Technology to be Reported at the AACR Annual Meeting
5. New Clinical Data for Cytogens Quadramet and Prostacint to be Reported at Upcoming Major Medical Meetings
6. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
7. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
8. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
9. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
10. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
11. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting